SEC Form 4 · accession 0001562180-17-000569
Syndax Pharmaceuticals Inc · SNDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Briggs Morrison
Officer — Chief Executive Officer · Director
Period of report
Feb 6, 2017
Accepted (ET)
Feb 8, 2017 · 2:13 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001395937
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $8.77 | Feb 6, 2017 | A | 160,000 | A | — | Feb 6, 2027 | Common Stock | 160,000 | 160,000 | D |
Explanation of responses
- F1The stock option will vest in 48 successive equal monthly installments measured from February 6, 2017.